VIGL vs. IMMP, OLMA, NGNE, RZLT, ATYR, CMPX, AVIR, CGC, ACIU, and CCCC
Should you be buying Vigil Neuroscience stock or one of its competitors? The main competitors of Vigil Neuroscience include Immutep (IMMP), Olema Pharmaceuticals (OLMA), Neurogene (NGNE), Rezolute (RZLT), Atyr PHARMA (ATYR), Compass Therapeutics (CMPX), Atea Pharmaceuticals (AVIR), Canopy Growth (CGC), AC Immune (ACIU), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry.
Vigil Neuroscience vs.
Immutep (NASDAQ:IMMP) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.
Immutep has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500.
2.3% of Immutep shares are held by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are held by institutional investors. 3.1% of Immutep shares are held by company insiders. Comparatively, 33.0% of Vigil Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Immutep's return on equity of 0.00% beat Vigil Neuroscience's return on equity.
Immutep received 283 more outperform votes than Vigil Neuroscience when rated by MarketBeat users. However, 82.86% of users gave Vigil Neuroscience an outperform vote while only 72.56% of users gave Immutep an outperform vote.
Immutep has higher revenue and earnings than Vigil Neuroscience.
In the previous week, Immutep and Immutep both had 1 articles in the media. Vigil Neuroscience's average media sentiment score of 0.93 beat Immutep's score of 0.33 indicating that Vigil Neuroscience is being referred to more favorably in the news media.
Immutep presently has a consensus target price of $8.50, indicating a potential upside of 345.03%. Vigil Neuroscience has a consensus target price of $19.75, indicating a potential upside of 858.74%. Given Vigil Neuroscience's higher possible upside, analysts plainly believe Vigil Neuroscience is more favorable than Immutep.
Summary
Immutep and Vigil Neuroscience tied by winning 6 of the 12 factors compared between the two stocks.
Get Vigil Neuroscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vigil Neuroscience Competitors List
Related Companies and Tools
This page (NASDAQ:VIGL) was last updated on 1/21/2025 by MarketBeat.com Staff
Free VIGL Stock Alerts